Bupivacaine Extended-Release Liposome Injection for Prolonged Postsurgical Analgesia in Patients Undergoing Hemorrhoidectomy: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial

医学 布比卡因 安慰剂 麻醉 类阿片 随机对照试验 局部麻醉剂 外科 止痛药 安慰剂对照研究 结直肠外科 双盲 腹部外科 内科学 替代医学 受体 病理
作者
Stephen R. Gorfine,Erol Onel,Gary Patou,Zoran Krivokapić
出处
期刊:Diseases of The Colon & Rectum [Lippincott Williams & Wilkins]
卷期号:54 (12): 1552-1559 被引量:345
标识
DOI:10.1097/dcr.0b013e318232d4c1
摘要

BACKGROUND: Bupivacaine extended-release liposome injection is a novel formulation of bupivacaine designed to achieve long-acting postoperative analgesia. OBJECTIVE: The aim of this study was to compare the magnitude and duration of postoperative analgesia from a single dose of bupivacaine extended-release injection with placebo administered intraoperatively in patients undergoing hemorrhoidectomy. DESIGN: This evaluation was a multicenter, randomized, double-blind, parallel-group, placebo-controlled phase 3 study. SETTINGS: Data were obtained from 13 centers in the Republic of Georgia, Poland, and Serbia. PATIENTS: Included in this study were patients aged 18 to 86 years undergoing excisional hemorrhoidectomy. INTERVENTIONS: All patients received either a single dose of bupivacaine extended-release 300 mg or placebo administered intraoperatively via wound infiltration. MAIN OUTCOME MEASURE: The cumulative pain score was assessed by measurement of the area under the curve of pain intensity through 72 hours after study drug administration. RESULTS: One hundred eighty-nine patients were randomly assigned and treated; 186 completed the study. Pain intensity scores were significantly lower in the bupivacaine extended-release group in comparison with the group receiving placebo (141.8 vs 202.5, P < .0001). More patients in the bupivacaine extended-release group remained opioid free from 12 hours (59%) to 72 hours (28%) after surgery compared with patients receiving placebo (14% and 10%; P < .0008 through 72 h). The mean total amount of opioids consumed through 72 hours was 22.3 mg and 29.1 mg in the bupivacaine extended-release and placebo groups (P ≤ .0006). The median time to first opioid use was 14.3 hours in the bupivacaine extended-release group vs 1.2 hours in the placebo group (P < .0001). A greater proportion of patients in the bupivacaine extended-release group were satisfied with their postsurgical analgesia (95% vs 73%, P = .0007) than in the placebo group. CONCLUSIONS: Bupivacaine extended-release demonstrated a statistically significant reduction in pain through 72 hours, decreased opioid requirements, delayed time to first opioid use, and improved patient satisfaction compared with placebo after hemorrhoidectomy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
我是老大的应助被一个懒虫采纳,获得10
刚刚
Reese关注了科研通微信公众号
刚刚
刚刚
研友_VZG7GZ的应助被滴滴答答采纳,获得10
刚刚
1秒前
CodeCraft的应助被初初初啊采纳,获得10
1秒前
何松发布了新的文献求助10
1秒前
魔幻苑睐发布了新的文献求助10
1秒前
冰激凌超人完成签到 ,获得积分10
1秒前
2秒前
2秒前
小蘑菇的应助被白晨采纳,获得10
2秒前
LB发布了新的文献求助10
2秒前
2秒前
2秒前
3秒前
aaaaassss发布了新的文献求助10
3秒前
rui完成签到,获得积分10
3秒前
孙浩文发布了新的文献求助10
3秒前
彭于晏的应助被牛牛小天使采纳,获得50
4秒前
4秒前
Lik发布了新的文献求助10
4秒前
李健的应助被干净沉鱼采纳,获得10
4秒前
4秒前
boxi完成签到,获得积分0
4秒前
乐空思的应助被wangpu采纳,获得20
4秒前
雷子发布了新的文献求助10
4秒前
4秒前
情怀的应助被mate采纳,获得10
4秒前
卜大大完成签到,获得积分20
4秒前
zm123的应助被zcyuqing采纳,获得10
5秒前
5秒前
领导范儿的应助被zasideler采纳,获得10
5秒前
ocean发布了新的文献求助10
5秒前
WxChen发布了新的文献求助10
5秒前
小马不叫宝莉完成签到,获得积分10
5秒前
5秒前
NexusExplorer的应助被funkii采纳,获得10
5秒前
Crystal完成签到,获得积分10
5秒前
活泼的幻丝完成签到,获得积分10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Markov Decision Processes and Reinforcement Learning 700
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8170166
求助须知:如何正确求助?哪些是违规求助? 9563213
关于积分的说明 21768986
捐赠科研通 7761665
什么是DOI,文献DOI怎么找? 3430630
关于科研通互助平台的介绍 2554458
邀请新用户注册赠送积分活动 2475393